Impaired fear memory in a rat model of the brain-derived neurotrophic factor Val66Met polymorphism is reversed by chronic exercise

Jaehne, Emily J.; Antolasic, Emily J.; Creutzberg, Kerstin Camile; Begni, Veronica; Riva, Marco; Buuse, Maarten van den

doi:10.1016/j.nlm.2023.107779

Cited by 1 publication

(2 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the presents study, we measured freezing rate as a severity of PTSD-like behavior. As mentioned, freezing behavior in fear-conditioning model of rodents can be considered as a PTSD-like behavior (Jaehne et al, 2023; Wisłowska-Stanek et al, 2023). However, further detailed studies are needed to better investigate Psilocybe cubensis effects on mood and cognition.…”

Section: Discussionmentioning

confidence: 99%

“…However, it should be noted that many studies use additional behavioral tests or behavioral phenotypes to completely approve PTSD-like behavior (Collins et al, 2023; Wisłowska-Stanek et al, 2023). But on the other hand, many studies only use freezing rate to assess PTSD-like behaviors (Jaehne et al, 2023; Mohammadi-Farani et al, 2022; Sur & Lee, 2022). Of note, previous study has suggested that multiple behaviors (or different behavioral paradigms) are needed to characterize the nature of traumatic stress effects on emotional memory (Biddle & Knox, 2023).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Psilocybe cubensis extract potently prevents fear memory recall and freezing behavior in short- but not long-term in a rat model of posttraumatic stress disorder.

Ghofrani-Jahromi,

Nouri-Darehno,

Rahimi-Danesh

et al. 2024

Behavioral Neuroscience

View full text Add to dashboard Cite

Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psilocin. Recent studies have shown the significant procognitive and mood-enhancer effects of Psilocybe cubensis. However, evidence is so limited, especially in preclinical studies. We aimed to investigate the effect of Psilocybe cubensis extract on posttraumatic stress disorder (PTSD)-like behavior, pain perception, locomotor activity, and anxiety in a rat model of PTSD. Male rats were exposed to three consecutive shocks (0.8 mA, 3 s interval) paired with three sounds broadcasted 3 s before delivering shocks (75 dB, 3 s). After 1, 3, or 21 days, freezing rate was measured in the fear-conditioning apparatus. Open filed test and hot plate were used to assess locomotor activity and anxiety, and pain subthreshold, respectively. Psilocybe cubensis was injected intraperitoneal at the dose of 25 mg/kg (single administration) before (pretrain) or after (posttrain) shocks, or before the test (pretest). Results showed psilocybin potently alleviated PTSD symptom is short-but not long-term after the induction of PTSD. Psilocybe cubensis decreased locomotor activity only in a short period after administration. Psilocybe cubensis also increased pain subthreshold and decreased anxiety. In conclusion, Psilocybe cubensis effects on PTSD-like behavior and locomotor activity seem to be remained in short-term, while Psilocybe cubensis effects on pain subthreshold and anxiety remained long-term. This is the first study evaluating the effect of Psilocybe cubensis on PTSD-like behavior in rats in three different time protocols (1, 3, and 21 days after fear conditioning).

show abstract

Section: Discussionmentioning

confidence: 99%